Anavex Life Sciences’ Promising Advances in Parkinson’s Therapy
Anavex Life Sciences is making significant strides in the treatment of Parkinson’s disease,
particularly with its investigational therapy, Anavex 2-73. Recent studies have
shown promising results, suggesting that the therapy could be a game-changer
for patients living with this debilitating condition.
A Phase 2 trial and its subsequent extension study have highlighted the potential of Anavex 2-73 in
reducing both dementia and motor...